Literature DB >> 22436355

Neuroprotective effects of chronic exposure of SH-SY5Y to low lithium concentration involve glycolysis stimulation, extracellular pyruvate accumulation and resistance to oxidative stress.

Riadh Nciri1, Frank Desmoulin, Mohamed Saleh Allagui, Jean-Claude Murat, Abdelfattah El Feki, Christian Vincent, Françoise Croute.   

Abstract

Recent studies suggest that lithium protects neurons from death induced by a wide array of neurotoxic insults, stimulates neurogenesis and could be used to prevent age-related neurodegenerative diseases. In this study, SH-SY5Y human neuronal cells were cultured in the absence (Con) or in the presence (Li+) of a low lithium concentration (0.5 mm Li2CO3, i.e. 1 mm lithium ion) for 25-50 wk. In the course of treatment, growth rate of Con and Li+ cells was regularly analysed using Alamar Blue dye. Resistance to oxidative stress was investigated by evaluating: (1) the adverse effects of high concentrations of lithium (4-8 mm) or glutamate (20-90 mm) on cell growth rate; (2) the levels of lipid peroxidation (TBARS) and total glutathione; (3) the expression levels of the anti-apoptotic Bcl-2 protein. In addition, glucose metabolism was investigated by analysing selected metabolites in culture media and cell extracts by 1H-NMR spectroscopy. As compared to Con, Li+ cells multiplied faster and were more resistant to stress, as evidenced by a lower dose-dependent decrease of Alamar Blue reduction and dose-dependent increase of TBARS levels induced by toxic doses of lithium and glutamate. Total glutathione content and Bcl-2 level were increased in Li+ cells. Glucose consumption and glycolytic activity were enhanced in Li+ cells and an important release of pyruvate was observed. We conclude that chronic exposure to lithium induces adaptive changes in metabolism of SH-SY5Y cells involving a higher cell growth rate and a better resistance to oxidative stress.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22436355     DOI: 10.1017/S1461145712000132

Source DB:  PubMed          Journal:  Int J Neuropsychopharmacol        ISSN: 1461-1457            Impact factor:   5.176


  16 in total

1.  Decreased AKT1/mTOR pathway mRNA expression in short-term bipolar disorder.

Authors:  Rodrigo Machado-Vieira; Marcus V Zanetti; Antonio L Teixeira; Miyuki Uno; Leandro L Valiengo; Marcio G Soeiro-de-Souza; Sueli M Oba-Shinjo; Rafael T de Sousa; Carlos A Zarate; Wagner F Gattaz; Suely K N Marie
Journal:  Eur Neuropsychopharmacol       Date:  2015-02-16       Impact factor: 4.600

Review 2.  Therapeutic Mechanisms of Lithium in Bipolar Disorder: Recent Advances and Current Understanding.

Authors:  Gin S Malhi; Tim Outhred
Journal:  CNS Drugs       Date:  2016-10       Impact factor: 5.749

3.  Na+/K+-ATPase level and products of lipid peroxidation in live cells treated with therapeutic lithium for different periods in time (1, 7, and 28 days); studies of Jurkat and HEK293 cells.

Authors:  Miroslava Vosahlikova; Lenka Roubalova; Hana Ujcikova; Martina Hlouskova; Stanislav Musil; Martin Alda; Petr Svoboda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2019-02-21       Impact factor: 3.000

4.  Tissue-specific protective properties of lithium: comparison of rat kidney, erythrocytes and brain.

Authors:  Lenka Roubalová; Miroslava Vošahlíková; Jiřina Slaninová; Jonáš Kaufman; Martin Alda; Petr Svoboda
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2021-01-06       Impact factor: 3.000

5.  Neuroprotective effect of Picholine virgin olive oil and its hydroxycinnamic acids component against β-amyloid-induced toxicity in SH-SY5Y neurotypic cells.

Authors:  Myra O Villareal; Kazunori Sasaki; Delphine Margout; Coralie Savry; Ziad Almaksour; Michel Larroque; Hiroko Isoda
Journal:  Cytotechnology       Date:  2016-05-07       Impact factor: 2.058

6.  α-Lipoic acid interaction with dopamine D2 receptor-dependent activation of the Akt/GSK-3β signaling pathway induced by antipsychotics: potential relevance for the treatment of schizophrenia.

Authors:  Jessica Deslauriers; Christian Desmarais; Philippe Sarret; Sylvain Grignon
Journal:  J Mol Neurosci       Date:  2012-09-14       Impact factor: 3.444

7.  The combination of lithium and l-Dopa/Carbidopa reduces MPTP-induced abnormal involuntary movements (AIMs) via calpain-1 inhibition in a mouse model: Relevance for Parkinson׳s disease therapy.

Authors:  Carol A Lazzara; Rebeccah R Riley; Anand Rane; Julie K Andersen; Yong-Hwan Kim
Journal:  Brain Res       Date:  2015-06-26       Impact factor: 3.252

8.  Impact of lithium alone or in combination with haloperidol on selected oxidative stress parameters in human plasma in vitro.

Authors:  Oliwia Gawlik-Kotelnicka; Wojciech Mielicki; Jolanta Rabe-Jabłońska; Dominik Strzelecki
Journal:  Redox Rep       Date:  2016-03-08       Impact factor: 4.412

Review 9.  Potential application of lithium in Parkinson's and other neurodegenerative diseases.

Authors:  Carol A Lazzara; Yong-Hwan Kim
Journal:  Front Neurosci       Date:  2015-10-27       Impact factor: 4.677

Review 10.  Chronic neuroprotective effects of low concentration lithium on SH-SY5Y cells: possible involvement of stress proteins and gene expression.

Authors:  Riadh Nciri; Ezzeddine Bourogaa; Samira Jbahi; Mohamed Salah Allagui; Abdelfattah Elfeki; Christian Vincent; Françoise Croute
Journal:  Neural Regen Res       Date:  2014-04-01       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.